Abstract
Risedronate sodium is an N-containing bisphosphonate that has been approved for the prevention and treatment of osteoporosis in postmenopausal women. An increase in the rate of bone remodelling is a regular feature of oestrogen withdrawal during the menopausal transition, but excessive remodelling leads to bone fragility. Risedronate and similar compounds reduce the rate of bone remodelling by suppressing the action of osteoclasts. The antifracture efficacy of risedronate is impressive. In large clinical trials of postmenopausal women with osteoporosis-related fracture(s) at entry, the risk of incident vertebral and non-vertebral fractures was reduced by ∼ 40%. In older women at risk for hip fracture, incident hip fractures were also reduced by ∼ 40%. Antifracture efficacy develops within the first 6 months, and treatment has been followed for as long as 5 years without deleterious effects on bone. We await reports of experience with risedronate in 'real-world' cases of greater complexity (i.e., in patients with co-morbidities and medications that would have excluded them from published clinical trials.
| Original language | English |
|---|---|
| Pages (from-to) | 465-477 |
| Number of pages | 13 |
| Journal | Expert Opinion on Pharmacotherapy |
| Volume | 6 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2005 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmacology (medical)
- Pharmacology, Toxicology and Pharmaceutics(all)
Cite this
Risedronate for prevention and treatment of osteoporosis in postmenopausal women. / Recker, Robert R.; Barger-Lux, Janet.
In: Expert Opinion on Pharmacotherapy, Vol. 6, No. 3, 03.2005, p. 465-477.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Risedronate for prevention and treatment of osteoporosis in postmenopausal women
AU - Recker, Robert R.
AU - Barger-Lux, Janet
PY - 2005/3
Y1 - 2005/3
N2 - Risedronate sodium is an N-containing bisphosphonate that has been approved for the prevention and treatment of osteoporosis in postmenopausal women. An increase in the rate of bone remodelling is a regular feature of oestrogen withdrawal during the menopausal transition, but excessive remodelling leads to bone fragility. Risedronate and similar compounds reduce the rate of bone remodelling by suppressing the action of osteoclasts. The antifracture efficacy of risedronate is impressive. In large clinical trials of postmenopausal women with osteoporosis-related fracture(s) at entry, the risk of incident vertebral and non-vertebral fractures was reduced by ∼ 40%. In older women at risk for hip fracture, incident hip fractures were also reduced by ∼ 40%. Antifracture efficacy develops within the first 6 months, and treatment has been followed for as long as 5 years without deleterious effects on bone. We await reports of experience with risedronate in 'real-world' cases of greater complexity (i.e., in patients with co-morbidities and medications that would have excluded them from published clinical trials.
AB - Risedronate sodium is an N-containing bisphosphonate that has been approved for the prevention and treatment of osteoporosis in postmenopausal women. An increase in the rate of bone remodelling is a regular feature of oestrogen withdrawal during the menopausal transition, but excessive remodelling leads to bone fragility. Risedronate and similar compounds reduce the rate of bone remodelling by suppressing the action of osteoclasts. The antifracture efficacy of risedronate is impressive. In large clinical trials of postmenopausal women with osteoporosis-related fracture(s) at entry, the risk of incident vertebral and non-vertebral fractures was reduced by ∼ 40%. In older women at risk for hip fracture, incident hip fractures were also reduced by ∼ 40%. Antifracture efficacy develops within the first 6 months, and treatment has been followed for as long as 5 years without deleterious effects on bone. We await reports of experience with risedronate in 'real-world' cases of greater complexity (i.e., in patients with co-morbidities and medications that would have excluded them from published clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=17144366238&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=17144366238&partnerID=8YFLogxK
U2 - 10.1517/14656566.6.3.465
DO - 10.1517/14656566.6.3.465
M3 - Review article
VL - 6
SP - 465
EP - 477
JO - Expert Opinion on Pharmacotherapy
JF - Expert Opinion on Pharmacotherapy
SN - 1465-6566
IS - 3
ER -